应用利妥昔单抗治疗视神经脊髓炎患者的有效性和安全性分析  

Efficacy and Safety of Rituximab in the Treatment of Optic Neuromyelitis Patients

作　　者：张海军[1] 张向东[1] ZHANG Hai-jun;ZHANG Xiang-dong(Anyang City People’s Hospital of Henan Province Department of Neurology,Anyang,Henan,455000,China)

机构地区：[1]河南省安阳市人民医院神经内科,河南安阳455000

出　　处：《临床研究》2018年第8期36-37,共2页Clinical Research

摘　　要：目的分析神经脊髓炎患者应用利妥昔单抗治疗的有效性和安全性。方法对本院2016年10月~2017年10月收治的106例视神经脊髓炎患者资料加以探究,按照随机数字表方法分成两组,各53例;对照组行常规药物治疗,实验组行利妥昔单抗治疗,比对两组效果及不良反应总发生率。结果治疗后,实验组视力评分较对照组更高(P<0.05);实验组膀胱直肠功能分值较对照组更低(P<0.05);实验组不良反应总发生率较之对照组更低(P<0.05)。结论 RTX治疗NMO患者可取得确切疗效,有效改善其视力及神经功能,且安全性高,具临床推广及应用价值。Objective To analyze the efficacy and safety of rituximab in patients with neuromyelitis.Methods The data of 106 patients with optic neuromyelitis treated in our hospital from October 2016 to October 2017 were investigated.According to the random number table method,the data were divided into two groups(n=53 in each group).The control group received conventional drug therapy.The experimental group Toximab treatment,compared with the two groups and the total incidence of adverse reactions.Results After treatment,the score of visual acuity in experimental group was higher than that of control group(P<0.05).The score of bladder rectum in experimental group was lower than that of control group(P<0.05).The total incidence of adverse reactions in the experimental group,which was lower than that in the control group(P<0.05).Conclusion RTX treatment of patients with NMO can achieve the exact effect,effectively improve their visual acuity and neurological function,and high safety,with clinical promotion and application value.

关 键 词：视神经脊髓炎 利妥昔单抗 有效性 安全性 

分 类 号：R774.6[医药卫生—眼科]